ETBX-071
AXP000158.1 · Cancer vaccine
- Platform
- adenovirus (Ad5 [E1-, E2b-])
- Targets
- KLK3
- Originator
- Etubics
- Sponsor
- ImmunityBio
Names
| Name | Type | Source |
|---|---|---|
| ETBX-071 | preferred name, code | curator, ncit |
| Adenoviral PSA Prostate Cancer Vaccine ETBX-071 ambiguous | synonym | ncit |
| Adenoviral PSA Vaccine ETBX-071 ambiguous | synonym | ncit |
Virus
- Role
- Vaccine vector
- Family
- Adenoviridae
- Virus
- human adenovirus 5 (NCBI Taxonomy 28285)
- Strain
- Ad5 [E1-, E2b-]
- Replication
- non replicating
- Modifications
- E1 and E2b regions deleted (replication-defective, reduced late gene expression)
- Transgenes
- prostate-specific antigen (KLK3)
- Route
- subcutaneous
- Source
- evidence
Cross-references
- NCI Thesaurus
- C148142
- FDA UNII
- 68TF9SDE9N
Approvals
No regulatory approval recorded.
Clinical trials (3)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT06765902 | Immunotherapy Before and After Surgery | Withdrawn | Phase 2 | 2025-12-15 | 2031-01-31 | 0 | High-risk Prostate Cancer |
| NCT06765954 | Immunotherapy With N 803, ETBX-071, and M-CENK in Combination With Radiation for Participants With High-Risk Prostate Cancer. | Withdrawn | Phase 2 | 2025-12-01 | 2031-01-31 | 0 | High-risk Prostate Cancer |
| NCT03481816 | Treatment of Castration Resistant Prostate Cancer Using Multi-Targeted Recombinant Ad5 PSA/MUC1/Brachyury Based Immunotherapy Vaccines | Completed | Phase 1 | 2018-07-24 | 2020-01-15 | 18 | Prostatic Cancer; Prostatic Neoplasms |
Recent changes
No changes recorded in its trials yet.
Clinical papers
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 33762322 | Phase I study of a multitargeted recombinant Ad5 PSA/MUC-1/brachyury-based immunotherapy vaccine in patients with metastatic castration-resistant prostate cancer (mCRPC). | Journal for immunotherapy of cancer | 2021 | cited by trial NCT03481816 |
Notes
Ad5 [E1-, E2b-] vector of the Etubics (now ImmunityBio) AdenoVerse-style platform, given subcutaneously; the E2b deletion is intended to allow repeat dosing despite pre-existing Ad5 immunity. Studied alone and in the multi-antigen Tri-Ad5 / 'Triad' regimens, which are combinations and not programs of their own. NCIt preferred name: Adenoviral PSA Vaccine ETBX-071.
How to cite
ETBX-071 (AXP000158.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000158.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.